|Bid||48.66 x 1000|
|Ask||48.66 x 900|
|Day's Range||48.36 - 49.09|
|52 Week Range||41.32 - 58.00|
|Beta (5Y Monthly)||0.29|
|PE Ratio (TTM)||19.08|
|Earnings Date||May 02, 2022 - May 06, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.62|
Qiagen NV (NYSE: QGEN) launched the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms. The new panel – currently for research use only (RUO) – comes in cartridge form to run on Qiagen's QIAstat-Dx automated syndromic testing devices. It tests for the two known forms of monkeypox virus (the so-called West African and Congo Basin clades), herpes simplex virus 1 & virus 2, human herpesvirus 6, var
HILDEN, Germany & GERMANTOWN, Md,, August 15, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms.
How far off is Qiagen N.V. ( NYSE:QGEN ) from its intrinsic value? Using the most recent financial data, we'll take a...